Description: InDex Pharmaceuticals Holding AB (publ), a pharmaceutical development company, develops pharmaceutical products for patients with ulcerative colitis. The company's lead drug candidate is Cobitolimod, which is in phase III clinical development for the treatment of patients with moderate to severe ulcerative colitis. It also develops a portfolio of other DNA based immunomodulatory sequences in preclinical stage for the treatment of various immunological diseases. The company was founded in 2000 and is headquartered in Solna, Sweden.
Home Page: www.indexpharma.com
Berzelius vAeg 13
Solna,
171 65
Sweden
Phone:
46 8 12 20 38 50
Officers
| Name | Title |
|---|---|
| Mr. Johan Gileus | Acting CEO & CFO |
| Dr. Charlotte Admyre | Chief Scientific Officer |
| Ms. Margareth Jorvid | Head of Regulatory Affairs |
| Ms. Eva Arlander | Chief Devel. Officer |
| Dr. Anders Broijersen | Chief Medical Officer |
Exchange: ST
Country: SE
Currency: Swedish krone (kr)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.2191 |
| Price-to-Sales TTM: | 7.4385 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 7 |